BioMedNewsBreaks

FridayDec 15, 2023 12:12 pm

BioMedNewsBreaks – Astiva Health Files Statement for Proposed IPO

Astiva Health is a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare. The organization today announced that it has started the process of registering its common shares on the Nasdaq Global Select, marking a crucial step for Astiva Health as it moves toward making a lasting impact in the healthcare industry. According to the announcement, the specifics of the number of shares to be offered and the price range are yet to be determined. The offer is contingent upon market conditions, and there is no assurance regarding the completion, size or terms of…

Continue Reading

ThursdayDec 14, 2023 3:41 pm

BioMedNewsBreaks — Why SOHM Inc. (SHMN) Is ‘One to Watch’

SOHM (OTC: SHMN) is a recognized generic pharmaceutical manufacturer with operations spanning India, the Philippines, Uganda, the U.S., U.K. and EU. The company aims to create and produce cutting-edge generic medications that span a wide range of treatment areas, all while ensuring top-tier quality and keeping prices affordable. “With proficiency in both manufacturing and marketing, SOHM stands out. The company holds licenses for producing over 300 products and has established distribution partnerships with firms in the United States, the Philippines and Uganda. Additionally, SOHM’s repertoire includes the launch of an innovative protein supplement, I-Prolec, featuring a distinct composition—a first-of-its-kind in…

Continue Reading

ThursdayDec 14, 2023 1:22 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Lead Drug Candidate Featured in Peer-Reviewed Publication Describing Brain Target Engagement in Neurodegenerative Diseases

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease and multiple sclerosis (“MS”), along with subsidiary Clene Nanomedicine, is announcing the publication of a peer-reviewed article describing brain target engagement by CNM-Au8(R), the company’s lead drug candidate. Coauthored by physician scientists from the University of Texas Southwestern Medical Center and Clene, the paper is titled “Evidence of Brain Target Engagement in Parkinson’s Disease and Multiple Sclerosis by the Investigational Nanomedicine, CNM-Au8, in the REPAIR Phase 2 Clinical Trials” and was published…

Continue Reading

ThursdayDec 14, 2023 1:03 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Combines AI, Proprietary Technology to Deliver Unprecedented Cardiac Insights

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced significant developments for the use of artificial intelligence (“AI”) applied to its proprietary vectorelectrocardiography (“VECG”) technology, as well as new leadership and advisory roles. By coupling machine learning methods with its VECG technology, HeartBeam aims to provide physicians with unprecedented diagnostic and prognostic insights about cardiac health that it believes will exceed the information provided by a standard 12-lead electrocardiogram (“ECG”). “It’s rare to acquire a large series of 12-lead ECGs from the same individual over time,” said Branislav Vajdic,…

Continue Reading

TuesdayDec 12, 2023 1:55 pm

BioMedNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Creates New Subsidiary, Announces Application of New Technology

Astrotech (NASDAQ: ASTC), an innovative science and technology company, has formed a new wholly owned subsidiary: Pro-Control Inc. According to the announcement, Pro-Control is unveiling its proprietary Pro-Control Maximum Value Process(TM) (Pro-Control MVP(TM) and the Pro-Control-1000(TM) mass spectrometer. The spectrometer has been designed to work within a chemical factory analyzing real-time samples while achieving optimized yields, quality and profits. It tests, measures and increases potency, purity and weight yields. Astrotech has entered into an exclusive license with Pro-Control to use the ATi mass spectrometer technology for chemical manufacturing process control applications. The Pro-Control MVP rapid test can take up to 20 tests…

Continue Reading

TuesdayDec 12, 2023 12:45 pm

BioMedNewsBreaks – Astiva Health Expands in Southern California, Now Enrolling Members in Three Counties

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, has announced strategic expansions into three Southern California counties: Los Angeles, Riverside and San Bernardino. The expansion, which the company called a “milestone” in its commitment to broadening access to quality healthcare, is effective Jan. 1, 2024; the company has already started enrolling members in these locations. According to the announcement, Astiva Health anticipates substantial growth in Medicare Advantage enrollment across these regions, noting that the cumulative effect of this expansion will increase the total target Medicare beneficiaries by approximately 259%. Astiva…

Continue Reading

TuesdayDec 12, 2023 11:00 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports on Preclinical Results from Psoriatic Human Skin Trial

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, has announced successful preclinical trial results of its innovative anti–IL–17 VHH antibody (“NanoAb”). The trial evaluated Scinai's NanoAbs as a local treatment for the large and underserved population of mild to moderate plaque psoriasis. The study was conducted by Genoskin, a French biotechnology company. According to the announcement, Genoskin's human skin models were induced for expression of plaque psoriasis symptoms, thereby enabling ex–vivo examination of the therapeutic effects of drugs targeting underlying mechanisms in the pathogenesis of plaque psoriasis, specifically the…

Continue Reading

MondayDec 11, 2023 12:31 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announced Peer-Reviewed Journal Publishes Data Supporting NanoAbs

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, is announcing the publication of a peer-reviewed article regarding NanoAbs. The article reports on data that supports the use of Scinai's aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases, which addresses significant medical needs. Titled “Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters,” the article is published in the prominent “Antiviral Research” journal. According to the announcement, the article focused on a new generation of anti-SARS-CoV-2 NanoAbs, identified…

Continue Reading

FridayDec 08, 2023 2:59 pm

BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients

Clene (NASDAQ: CLNN), together with its wholly owned subsidiary Clene Nanomedicine Inc., recently provided operating highlights for its amyotrophic lateral sclerosis (“ALS”) clinical program. “In August, Clene reported a 24-month long-term data cut from the open-label extension (‘OLE’) of the RESCUE-ALS study as of July 2023, which showed a significant median survival benefit of 19.3 months in addition to a significant (p=0.049) 52% decreased risk of ALS clinical worsening events – defined as the first occurrence of death, tracheostomy (a procedure that involves creating an opening in the neck into the windpipe to help air and oxygen reach the lungs),…

Continue Reading

ThursdayDec 07, 2023 1:08 pm

BioMedNewsBreaks — Branded Legacy Inc. (BLEG) Retires 400M Common Shares, Announces Other Key Moves to Enhance Shareholder Value

Branded Legacy (OTC: BLEG), a leader in the biotech industry, has retired an additional 400,000,000 shares of its common stock, bringing the total number of shares retired to two billion. According to the announcement, the retirement of these stocks marks a “significant move” in the company's commitment to enhancing shareholder value, which also includes a broader strategy to streamline share structure and improve market standing. The announcement also noted recent acquisitions that have contributed to increasing the company’s assets portfolio to more than $1 million this month. In the announcement, the company also noted that it has purchased ultraefficient analytical and chemical…

Continue Reading